Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Roviello G, Gambale E, De Gennaro Aquino I, Maruzzo M, Messina C, Vascotto IA, Rossi V, Bimbatti D, Erbetta E, Messina M, Mennitto A, Rebuzzi SE, Nasso C, Mercinelli C, Catalano M, Maiorano BA, Fanelli M, Sorarù M, Scolari F, Mela MM, Galli L, Salfi A, Rizzo M, Puglisi S, Orlando V, Fornarini G, Rametta A, Giannatempo P, Cerbone L, Doni L, Pillozzi S, Antonuzzo L

Open source

DOI: 10.3389/fimmu.2026.1818239
Published: 2026
Container: Frontiers in immunology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1818239,
  title = {Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.},
  author = {Roviello G and Gambale E and De Gennaro Aquino I and Maruzzo M and Messina C and Vascotto IA and Rossi V and Bimbatti D and Erbetta E and Messina M and Mennitto A and Rebuzzi SE and Nasso C and Mercinelli C and Catalano M and Maiorano BA and Fanelli M and Sorarù M and Scolari F and Mela MM and Galli L and Salfi A and Rizzo M and Puglisi S and Orlando V and Fornarini G and Rametta A and Giannatempo P and Cerbone L and Doni L and Pillozzi S and Antonuzzo L},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1818239},
  url = {https://doi.org/10.3389/fimmu.2026.1818239}
}

RIS

TY  - JOUR
TI  - Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.
AU  - Roviello G
AU  - Gambale E
AU  - De Gennaro Aquino I
AU  - Maruzzo M
AU  - Messina C
AU  - Vascotto IA
AU  - Rossi V
AU  - Bimbatti D
AU  - Erbetta E
AU  - Messina M
AU  - Mennitto A
AU  - Rebuzzi SE
AU  - Nasso C
AU  - Mercinelli C
AU  - Catalano M
AU  - Maiorano BA
AU  - Fanelli M
AU  - Sorarù M
AU  - Scolari F
AU  - Mela MM
AU  - Galli L
AU  - Salfi A
AU  - Rizzo M
AU  - Puglisi S
AU  - Orlando V
AU  - Fornarini G
AU  - Rametta A
AU  - Giannatempo P
AU  - Cerbone L
AU  - Doni L
AU  - Pillozzi S
AU  - Antonuzzo L
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1818239
UR  - https://doi.org/10.3389/fimmu.2026.1818239
ER  -

APA

G, R., E, G., I, D. G. A., M, M., C, M., IA, V., V, R., D, B., E, E., M, M., A, M., SE, R., C, N., C, M., M, C., BA, M., M, F., M, S., F, S., MM, M., L, G., A, S., M, R., S, P., V, O., G, F., A, R., P, G., L, C., L, D., S, P., & L, A. (2026). Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1818239

Source records

pubmed · retrieved 2026-09-26T06:07:59.067Z